Efficacy of Epidermal Growth Factor Receptor (EGFR) inhibitor Panitumumab for the treatment of KRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Panitumumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Nov 2019 Status changed from recruiting to suspended.
- 17 Nov 2017 Planned initiation date changed from 15 May 2017 to 1 Nov 2017.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.